Literature DB >> 20625699

[Targeted prevention of posttraumatic stress disorder].

J Hellmann1, I Heuser, G Kronenberg.   

Abstract

Posttraumatic stress disorder (PTSD) is a severe, frequently chronic condition with a high rate of co-morbidity with other psychiatric syndromes. In contrast to the majority of psychiatric disorders, the traumatic event in PTSD constitutes a clearly defined etiological factor. A growing understanding of the mechanisms contributing to the development of PTSD has highlighted the possibilities for early preventive psychological and pharmacological treatment during the so-called golden hours after a traumatic experience. Whereas preliminary evidence suggests that a pharmacological recalibration of the HPA system and cognitive behavioral therapy may be helpful, other frequently used strategies, such as psychological debriefing or benzodiazepine treatment, seem to be largely ineffective, possibly even worsening PTSD symptoms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20625699     DOI: 10.1007/s00115-010-3064-y

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  44 in total

Review 1.  The transition from memory retrieval to extinction.

Authors:  Martín Cammarota; Daniela M Barros; Mónica R M Vianna; Lia R M Bevilaqua; Adriana Coitinho; Germán Szapiro; Luciana A Izquierdo; Jorge H Medina; Iván Izquierdo
Journal:  An Acad Bras Cienc       Date:  2004-08-23       Impact factor: 1.753

Review 2.  Amygdala, medial prefrontal cortex, and hippocampal function in PTSD.

Authors:  Lisa M Shin; Scott L Rauch; Roger K Pitman
Journal:  Ann N Y Acad Sci       Date:  2006-07       Impact factor: 5.691

3.  Posttraumatic stress disorder and the incidence of nicotine, alcohol, and other drug disorders in persons who have experienced trauma.

Authors:  Naomi Breslau; Glenn C Davis; Lonni R Schultz
Journal:  Arch Gen Psychiatry       Date:  2003-03

Review 4.  An animal model of posttraumatic stress disorder: the use of cut-off behavioral criteria.

Authors:  Hagit Cohen; Joseph Zohar
Journal:  Ann N Y Acad Sci       Date:  2004-12       Impact factor: 5.691

Review 5.  Corticotropin-releasing hormone in depression and post-traumatic stress disorder.

Authors:  J W Kasckow; D Baker; T D Geracioti
Journal:  Peptides       Date:  2001-05       Impact factor: 3.750

Review 6.  Epidemiologic studies of trauma, posttraumatic stress disorder, and other psychiatric disorders.

Authors:  Naomi Breslau
Journal:  Can J Psychiatry       Date:  2002-12       Impact factor: 4.356

7.  Low-dose cortisol for symptoms of posttraumatic stress disorder.

Authors:  Amanda Aerni; Rafael Traber; Christoph Hock; Benno Roozendaal; Gustav Schelling; Andreas Papassotiropoulos; Roger M Nitsch; Ulrich Schnyder; Dominique J-F de Quervain
Journal:  Am J Psychiatry       Date:  2004-08       Impact factor: 18.112

8.  PTSD diagnoses, subsyndromal symptoms, and comorbidities contribute to impairments for breast cancer survivors.

Authors:  Rebecca A Shelby; Deanna M Golden-Kreutz; Barbara L Andersen
Journal:  J Trauma Stress       Date:  2008-04

9.  Urinary free-cortisol levels in posttraumatic stress disorder patients.

Authors:  J W Mason; E L Giller; T R Kosten; R B Ostroff; L Podd
Journal:  J Nerv Ment Dis       Date:  1986-03       Impact factor: 2.254

10.  The effect of propranolol on posttraumatic stress disorder in burned service members.

Authors:  Laura L McGhee; Christopher V Maani; Thomas H Garza; Peter A Desocio; Kathryn M Gaylord; Ian H Black
Journal:  J Burn Care Res       Date:  2009 Jan-Feb       Impact factor: 1.845

View more
  2 in total

Review 1.  [Prophylaxis and therapy of post-traumatic stress disorder with propranolol: evidence and ethical analysis].

Authors:  K Kühlmeyer; R J Jox
Journal:  Nervenarzt       Date:  2013-10       Impact factor: 1.214

2.  [Posttraumatic stress disorder : Trigger and consequence of vascular diseases].

Authors:  J Schöner; G Kronenberg; A Heinz; M Endres; K Gertz
Journal:  Nervenarzt       Date:  2017-03       Impact factor: 1.214

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.